| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| Other Sizes |
| ln Vitro |
Neomycin is efficient against Pseudomonas aeruginosa and anaerobic bacteria, but not the majority of Gram-negative bacteria. Its increased efficacy against Staphylococcus aureus is occasionally restricted to Gram bacteria, but prolonged use results in bacterial pathogenicity [1].
|
|---|---|
| Animal Protocol |
For the chicken chorioallantoic membrane (CAM) assay, fertilized chicken eggs were used. Samples (5 μl volume) containing angiogenin (10 ng), neomycin (4-200 ng), or combinations were applied to the CAM. Growth of blood vessels was observed microscopically and recorded as either positive or negative after 48 hours of incubation [2].
|
| References | |
| Additional Infomation |
Neomycin sulfate is the sulfate form of neomycin, a broad-spectrum aminoglycoside antibiotic derived from Streptomyces fradiae, possessing antibacterial activity. Neomycin is an antibiotic complex composed of three components: two isoforms, B and C, are the active ingredient, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. Therefore, the drug interferes with the assembly of the initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. Furthermore, neomycin induces misreading of the mRNA template, leading to frameshift translation and premature termination of translation. Ultimately, this results in bacterial cell death.
An aminoglycoside antibiotic complex produced by Streptomyces fradiae. It consists of neomycin A, B, and C, and exerts its effect by inhibiting translation during protein synthesis. See also: Neomycin sulfate (note moved to). |
| Exact Mass |
614.312
|
|---|---|
| CAS # |
1405-10-3
|
| Related CAS # |
Framycetin;119-04-0
|
| PubChem CID |
62403
|
| Appearance |
White to light yellow solid powder
|
| Boiling Point |
1046.1ºC at 760 mmHg
|
| Melting Point |
>187°C (dec.)
|
| Flash Point |
586.5ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| Index of Refraction |
56 ° (C=10, H2O)
|
| Hydrogen Bond Donor Count |
15
|
| Hydrogen Bond Acceptor Count |
23
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
47
|
| Complexity |
953
|
| Defined Atom Stereocenter Count |
18
|
| SMILES |
S(=O)(=O)(O[H])O[H].O([C@]1([H])[C@]([H])([C@]([H])([C@]([H])(C([H])([H])O[H])O1)O[C@@]1([H])[C@@]([H])([C@@]([H])([C@]([H])([C@]([H])(C([H])([H])N([H])[H])O1)O[H])O[H])N([H])[H])O[H])[C@]1([H])[C@]([H])([C@@]([H])(C([H])([H])[C@]([H])([C@@]1([H])O[C@]1([H])[C@]([H])([C@@]([H])([C@]([H])([C@]([H])(C([H])([H])N([H])[H])O1)O[H])O[H])N([H])[H])N([H])[H])N([H])[H])O[H]
|
| InChi Key |
OIXVKQDWLFHVGR-GQTDVWSESA-N
|
| InChi Code |
InChI=1S/C23H46N6O13.H2O4S/c24-2-7-13(32)15(34)10(28)21(37-7)40-18-6(27)1-5(26)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(29)16(35)14(33)8(3-25)38-22;1-5(2,3)4/h5-23,30-36H,1-4,24-29H2;(H2,1,2,3,4)/t5-,6+,7-,8+,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22?,23+;/m1./s1
|
| Chemical Name |
(2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol;sulfuric acid
|
| Synonyms |
Framycetin Neomycin BNeomycinMycifradin Soframycin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~250 mg/mL (~275.06 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (55.01 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05593601 | RECRUITING | Drug: Neomycin | Colonization, Asymptomatic | Mahidol University | 2022-11-24 | Phase 4 |
| NCT01227863 | UNKNOWN STATUS | Drug: MAXINOM® Drug: Maxitrol® |
Acute Bacterial Conjunctivitis |
Azidus Brasil | 2011-02 | Phase 3 |
| NCT05779254 | RECRUITING | Drug: Neomycin Sulfate | Anastomotic Leak Microbial Colonization |
Uzsoki Hospital | 2023-02-01 | |
| NCT02001909 | COMPLETED | Drug: Regorafenib (Stivarga, BAY73-4506) Drug: Neomycin |
Neoplasms | Bayer | 2013-12 | Phase 1 |
| NCT00534391 | UNKNOWN STATUS | Drug: neomycin sulfate, polymyxin B sulfate and gramicidin Drug: Artificial tear |
Hordeolum | Chulalongkorn University | 2007-09 | Phase 3 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
